semaglutide (Ozempic, Wegovy), liraglutide, exendin-4, tirzepatide, etc., as weight-loss medications, while the ability of GLP-1 receptor agonists (GLP-1RAs) to decrease blood sugar and to increase insulin secretion have led to their use in treating Type 2 Diabetes [15]
inject slowly
Regarding safety profile, in phase 2 trials for obesity and diabetes, mazdutide was discontinued due to AE by 02% of participants and SAE experienced by up to 7% of participants with mazdutide 6 mg (Tables 2 and 3)
68 Since these changes were attributed to suppression of de novo bile acid synthesis and an escalation in reverse cholesterol transport, future research was focused on development of FXR agonists that would have better efficacy, safety and tolerability profiles
Because of its importance in growth and other key bodily functions, its crucial for IGF-1 levels to stay in proper balance
For full prescribing information, please consult your provider or review the medication safety information